Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

Bibliographic Details
Main Authors:	Rajshekhar Chakraborty, Divaya Bhutani, Mathew S. Maurer, Meera Mohan, Suzanne Lentzsch, Anita D’Souza
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-11-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00950-3

Similar Items

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
by: Rajshekhar Chakraborty, et al.
Published: (2023-08-01)

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
by: Meera Mohan, et al.
Published: (2024-03-01)

Editorial: Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis
by: Divaya Bhutani, et al.
Published: (2023-02-01)

Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; referees: 2 approved]
by: Talha Badar, et al.
Published: (2018-08-01)

Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type
by: Eli Muchtar, et al.
Published: (2016-09-01)

Localized Immunoglobulin Light-Chain Amyloidosis of the Ulnar Nerve
by: Shinsuke Morisaki, et al.
Published: (2021-05-01)

Use of daratumumab in high risk multiple myeloma: A meta‐analysis
by: Vikram Premkumar, et al.
Published: (2020-07-01)

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
by: Nelson Leung, et al.
Published: (2023-11-01)

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis
by: Katherine M. Bever, et al.
Published: (2016-01-01)

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis
by: Shayna Sarosiek, et al.
Published: (2022-11-01)

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
by: Jipeng Yan, et al.
Published: (2022-10-01)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
by: M. Hasib Sidiqi, et al.
Published: (2021-05-01)

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
by: Hughes MS, et al.
Published: (2023-12-01)

Localized Lymph Node Light Chain Amyloidosis
by: Binod Dhakal, et al.
Published: (2015-01-01)

Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
by: George Mellgard, et al.
Published: (2024-03-01)

A prospective study of nutritional status in immunoglobulin light chain amyloidosis
by: Prayman T. Sattianayagam, et al.
Published: (2013-01-01)

Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis
by: Kaini Shen, et al.
Published: (2024-01-01)

Amyloid Goiter as the First Recognizable Manifestation of Immunoglobulin Light Chain Amyloidosis
by: John J. Orrego, MD, et al.
Published: (2019-09-01)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
by: Anita D’Souza, et al.
Published: (2021-04-01)

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
by: Christopher E. Jensen, et al.
Published: (2022-06-01)

Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications
by: Linchun Xu, et al.
Published: (2021-07-01)

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients
by: Mathijs O. Versteylen, et al.
Published: (2022-07-01)

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
by: Morie A. Gertz, et al.
Published: (2008-09-01)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
by: Giuseppe Vergaro, MD, PhD, et al.
Published: (2021-03-01)

Amyloid cranial polyneuropathy: A rare neurological presentation of immunoglobulin light‐chain amyloidosis
by: Abhinav Agarwal, et al.
Published: (2021-03-01)

Oxidative damage in immunoglobulin light chain and transthyretin cardiac amyloidosis – a closer look
by: Elena Cavallone, et al.
Published: (2024-05-01)

Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
by: Tanya L Poshusta, et al.
Published: (2009-01-01)

LIGHT CHAIN AMYLOIDOSIS
by: Paolo Milani, et al.
Published: (2018-03-01)

The Clinical Characteristics of Immunoglobulin Light Chain Amyloidosis in the Chinese Population: A Systematic Scoping Review
by: Chengcheng Fu, et al.
Published: (2022-12-01)

T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab‐based therapy
by: Yujia Wang, et al.
Published: (2021-11-01)

The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis
by: Niki Lama, et al.
Published: (2022-03-01)

In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database
by: Tiffany P Quock, et al.
Published: (2022-12-01)

Light-Chain Cardiac Amyloidosis
by: Gonzalo Barge-Caballero, MD, et al.
Published: (2019-10-01)

Prognostic factors in Chinese patients with immunoglobulin light chain amyloidosis: a scoping review and meta-analysis
by: Yu Wu, et al.
Published: (2024-12-01)

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts
by: Iman Meziane, et al.
Published: (2017-10-01)

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial
by: Vaishali Sanchorawala, et al.
Published: (2013-05-01)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
by: Cameron S. Fraser, et al.
Published: (2022-10-01)

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
by: Paolo Swuec, et al.
Published: (2019-03-01)

Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis
by: Ashima Singh, et al.
Published: (2024-05-01)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
by: Kristine Frerichs, et al.
Published: (2023-08-01)